**Babesia microti**: Pathogen Genomics, Genetic Variability, Immunodominant Antigens, and Pathogenesis

Ankit Puri¹, Surabhi Bajpai², Scott Meredith³, L. Aravind⁴, Peter J. Krause⁵* and Sanjai Kumar¹

¹ Laboratory of Emerging Pathogens, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States, ² Department of Bioscience and Biotechnology, Banasthali Vidyapith, Banasthali, India, ³ National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD, United States, ⁴ Department of Epidemiology of Microbial Diseases, Yale School of Public Health and Yale School of Medicine, New Haven, CT, United States

More than 100 *Babesia* spp. tick-borne parasites are known to infect mammalian and avian hosts. *Babesia* belong to Order Piroplasmid ranked in the Phylum Apicomplexa. Recent phylogenetic studies have revealed that of the three genera that constitute Piroplasmida, *Babesia* and *Theileria* are polyphyletic while *Cytauxzoon* is nested within a clade of *Theileria*. Several *Babesia* spp. and sub-types have been found to cause human disease. *Babesia microti*, the most common species that infects humans, is endemic in the Northeastern and upper Midwestern United States and is sporadically reported elsewhere in the world. Most infections are transmitted by Ixodid (hard-bodied) ticks, although they occasionally can be spread through blood transfusion and rarely via perinatal transmission and organ transplantation. Babesiosis most often presents as a mild to moderate disease, however infection severity ranges from asymptomatic to lethal. Diagnosis is usually confirmed by blood smear or polymerase chain reaction (PCR). Treatment consists of atovaquone and azithromycin or clindamycin and quinine and usually is effective but may be problematic in immunocompromised hosts. There is no human *Babesia* vaccine. *B. microti* genomics studies have only recently been initiated, however they already have yielded important new insights regarding the pathogen, population structure, and pathogenesis. Continued genomic research holds great promise for improving the diagnosis, management, and prevention of human babesiosis, and in particular, the identification of lineage-specific families of cell-surface proteins with potential roles in cytoadherence, immune evasion and pathogenesis.

**Keywords**: *Babesia microti*, biomarkers, genomics, pathogen, population genetics, tick-borne diseases

**INTRODUCTION**

Human babesiosis is an emerging tick-borne disease caused by several *Babesia* species found in the temperate regions of the world. *Babesia* and related *Theileria* organisms are intraerythrocytic parasites that belong to the same phylum (Apicomplexa) as *Plasmodia* with which they share several microbiologic and pathogenic features. Among the many *Babesia* species
that can infect humans, Babesia microti is the most prevalent and the primary cause of human babesiosis. Disease due to this pathogen is endemic in the Northeastern and northern Midwestern United States and reported sporadically in other temperate regions of the world (Figure 1) (Homer et al., 2000; Matsui et al., 2000; Hunfeld et al., 2008; Vannier and Krause, 2012; Zhou et al., 2014; Liu et al., 2017). B. microti is primarily transmitted by Ixodes scapularis ticks but also through blood transfusion, organ transplantation, and perinatally (Fox et al., 2006; Herwaldt et al., 2011; Brennan et al., 2016). Other Babesia spp. that are known to infect humans include Babesia crassa-like agent, Babesia divergens, B. divergens-like agent, Babesia duncani, B. microti-like agent, Babesia motasi, and Babesia venatorum. A comprehensive list of Babesia spp. that are reported to cause human babesiosis, their areas of transmission, reservoir hosts and tick-vectors are provided in Table 1.

Most Babesia spp. are small (1–5 μm in length) and are pear-shaped, oval, or round with blue cytoplasm and red chromatin dots (DNA) when viewed on Giemsa-stained blood smears (Healy and Ruebush, 1980). Ring forms are the most common configurations noted on blood smears and are similar to those of Plasmodium falciparum. Babesia differ from P. falciparum by the absence of hemozoin pigment deposit in the ring form, the lack of schizonts and banana-shaped gametocytes, and the presence of tetrads (Maltese cross) (Figure 2) (Vannier and Krause, 2012). The latter are seldom noted but, if present, are pathognomonic of Babesia.

Babesiosis usually causes mild to moderate illness but asymptomatic infection may occur, and severe life-threatening disease occurs in immunocompromised hosts, such as those with asplenia, cancer, HIV/AIDS, the extremes of age (neonates and those over 50 years), and people taking immunosuppressive drugs (Falagas and Klempern, 1996; Hatcher et al., 2001; Froberg et al., 2004; Krause et al., 2008; Vannier and Krause, 2012; Menis et al., 2015; Dumić et al., 2020). Complications include acute respiratory distress syndrome (ARDS), severe anemia, congestive heart failure, disseminated intravascular coagulopathy (DIC), liver and renal failure, and shock (Hatcher et al., 2001; Krause et al., 2007; Dumić et al., 2020). We have a limited understanding of the pathogenesis of babesiosis but excessive proinflammatory cytokine production, cytoadherence of infected red blood cells, and severe anemia are posited as important pathologic mechanisms (Clark and Jacobson, 1998; Hemmer et al., 2000; Allred and Al-Kheder, 2004; Krause et al., 2007). Diagnosis is suspected on epidemiologic and clinical grounds and confirmed by blood smear and/or polymerase chain reaction (PCR; Krause et al., 2021). Treatment is generally effective with the use of atovaquone and azithromycin or clindamycin and quinine but may be problematic in highly immunocompromised hosts where acute fulminant disease may be fatal or prolonged antibiotic therapy may lead to antibiotic resistance (Krause et al., 2000, 2021; Wormser et al., 2010; Lemieux et al., 2016; Simon et al., 2017).

Genomics is the branch of molecular biology that focuses on the structure, function, evolution, and mapping of genomes. It aims at the characterization and quantification of all the genes and their interactions that affect the function of the organism. B. microti genomic studies have only recently been initiated but already have delivered important new insights regarding pathogen genomic structure, population structure, evolution, and pathogenesis; as well as biomarkers of detection, drug resistance markers, targets for novel therapeutics, and vaccines (Figure 3).

**Babesia microti PATHOGEN GENOMICS**

**Babesia microti Genome Organization**
The B. microti genome sequence was first published in 2012 (Cornillot et al., 2012). The B. microti genome is comprised of 4 chromosomes that contains approximately 6.5 megabase pairs (Mbp) that encode around 3,500 polypeptides, which is the smallest of all Apicomplexan genomes (Cornillot et al., 2012). A reannotation analysis of the B. microti genome sequence has identified 3,615 genes which encode for 3,567 proteins (Silva et al., 2016). A salient feature of the B. microti genome is the preponderance of unusually small introns that range in size between 18 and 21 base pairs, some of which are reported to be in frame, which is rare in eukaryotes (Silva et al., 2016). In contrast to the concentrated form of the mitochondrial genome in Plasmodium parasites, B. microti possesses a linear monomeric mitochondrial genome which contains a pair of unique repeats and a flip-flop inversion system. The flip-flop inversions may be involved in the switch on or off expression of the B. microti mitochondrial genes and gene fragments in their life cycle (Hikosaka et al., 2012).

In apicomplexan parasites, colocalization of virulence genes has been shown to influence spatial genome organization and is linked to virulence and survival (Bunnik et al., 2019). In P. falciparum, members belonging to multi-gene families that are responsible for virulence, antigenic variation, and immune evasion are colocalized in the genome (Reid, 2015; Bunnik et al., 2018, 2019). Studies of the comparative 3D genome organization of apicomplexan parasites has revealed that B. microti has a classical Rabl organization, which is similar to yeast and lacks a clear localization of virulent factor genes as seen with the P. falciparum parasite (Lenz and Le Roch, 2019). Thus, the B. microti genome organization is not strongly linked to the regulation of virulence genes.

**Babesia microti Phylogeny and Taxonomy**
The apicomplexan clade of Hematozoa, which includes parasites infecting vertebrate hemocytes, is further divided into two major clades – the well-studied Haemosporidia, such as Plasmodium, and the Piroplasmida. Piroplasmida includes the traditionally defined genera such as Babesia and Theileria. Phylogenetic analyses based on the nucleus-encoded genes revealed that the recently described parasites/symbionts of the ascidian tunicates, Cardiosporidium (infecting Ciona) and Nephromyces (infecting Molgula) have emerged as a sister-group of all Hematozoa (Munoz-Gomez et al., 2019). These parasites are monoxenous (i.e., complete their life cycle in a single host species), unlike the crown group Hematozoa which have a definitive invertebrate host and a secondary
FIGURE 1 | Geographic range of Ixodes-tick vectors and location of human babesiosis reports. The lighter colors represent the geographical range of several Ixodes tick species known or suspected to transmit Babesia parasites to humans but where human babesiosis is rare (<5 cases), unreported or absent. Ixodes ricinus and Ixodes persulcatus are sympatric in southern Finland, Estonia, Latvia, and northwestern Russia, while I. persulcatus and Ixodes ovatus are both enzootic in Hokkaido in northern Japan. The darker colors represent regions where human babesiosis is endemic or sporadic (defined by ≥5 cases). Circles indicate single cases, except in three locations (Mexico, Montenegro, and eastern Poland) where all patients at these locations were reported from the same hospital. Colors indicate Babesia species: red for B. microti, orange for B. duncanii, blue for B. divergens, green for B. venatorum, pink for B. crassa-like agent, black for KO-1, yellow for Babesia spp. XXB/HangZhou, and white for undetermined Babesia spp. The map does not show asymptomatic cases and travel-associated cases [adapted from Vannier and Krause (2012) and (Ryan et al., 2019) from The New England Journal of Medicine, Edouard Vannier, PhD., and Peter J. Krause, M.D., Human Babesiosis, 366, 2399. Copyright (2012) Massachusetts Medical Society. Reprinted with permission.}

vertebrate host (Munoz-Gomez et al., 2019). This suggests that the transition from monoxenous blood-parasitism in ascidians, a sister group of the vertebrates, to the dixenous parasitism typical of Hematozoa happened early in their evolution with the emergence of invertebrate blood-feeders that could serve as vectors. While piroplasms retain many of the features of this ancestral vertebrate blood parasite, species classified in the genus Babesia exhibit specialized modes of transmission, such as transovarial transmission from females to their offspring, as well as transstadial transmission between different stages in the life cycle of the tick vector. These features appear to have emerged as adaptations to their arachnid vectors.

Traditionally, piroplasms have been classified based on morphological/life-history features such as presence (Theileria and Cytauxzoon) or absence (Babesia) of schizogony; as well as size- “small” species (e.g., B. microti and B. duncanii) versus “large” species (e.g., Babesia bigemina). However, a series of molecular phylogenetic studies over the past decade (reviewed in Jalovecka et al., 2019) using nuclear and apicoplast sequences have shown that the traditional morphological taxonomy of Babesia and allied genera does not reflect their true evolutionary relationships. Notably, these studies have shown that the genera of Babesia and Theileria are not monophyletic and that the genus Cytauxzoon is nested with the lineages that have been assigned to the former two genera (Lack et al., 2012). Instead, these studies suggest that the Babesia-Theileria-Cytauxzoon complex can be divided into 10 monophyletic clades that encompass 14 reference species included in the genus Babesia, 9 species included in Theileria and 2 species included in Cytauxzoon. Piroplasms infect a wide range of eutherian mammals, marsupials (e.g., Theileria spp. Clade IV), monotremes (Theileria ornithorhynchii, Clade II) and birds (e.g., Babesia ugwidiensis, Clade V) (Schnittger et al., 2012). While reptilian-parasitic piroplasms, such as Sauroploasma and Serpentoplasma have been reported (Adl et al., 2019), their relationship to the above complex remains unclear. Nevertheless, the widespread presence of the Babesia-Theileria-Cytauxzoon complex in warm-blooded vertebrates suggests that they have likely emerged early in the history of these vertebrates and have repeatedly jumped hosts (Jalovecka et al., 2019).

Consistent with this possibility, human parasitism among piroplasms has emerged on multiple occasions, most likely through accidental extension of the parasite host range due to interactions with ticks feeding on infected domesticates or wildlife. Of these, the B. microti-like group, defines “clade 1,”
TABLE 1 | Babesia that cause human babesiosis.

| Babesia species       | Year Discovered/Reported | Major Region of Transmission         | Primary vector |
|-----------------------|--------------------------|--------------------------------------|----------------|
| Babesia microti       | 1968<sup>a</sup>         | United States (Northeast, northern Midwest) | Ixodes scapularis |
| Babesia divergens     | 1957<sup>bc</sup>        | Western Europe                        | Ixodes ricinus |
| Babesia duncani       | 1991<sup>c</sup>         | United States (Farwest)               | Dermacentor albipictus |
| Babesia venatorum     | 2003<sup>d</sup>         | Europe, China                         | I. ricinus and Ixodes persulcatus |
| Babesia motasi        | 2007<sup>e</sup>         | South Korea                           | Unknown        |
| Babesia crassa-like   | 2018<sup>f</sup>         | Northeast China                       | I. persulcatus |
| Babesia divergens-like| 1996<sup>g</sup>         | United States                         | Unknown        |
| Babesia microti-like  | 1997<sup>h</sup>         | Taiwan, Japan                         | Unknown        |

<sup>a</sup>Scholtens et al. (1968); <sup>b</sup>Skrabalo and Deanovic (1957) (probable B. divergens); <sup>c</sup>Quick et al. (1993); <sup>d</sup>Herwaldt et al. (2003); <sup>e</sup>Kim et al. (2007); <sup>f</sup>Jia et al. (2018); <sup>g</sup>Herwaldt et al. (1996); <sup>h</sup>Shih et al. (1997).

FIGURE 2 | Developmental stages of intraerythrocytic Babesia microti parasite by Giemsa-stained thin blood microscopy. (A) Ring form with cytoplasm stained blue; (B) mature trophozoite with two small nuclei; (C) a tetrad (Maltese cross); and (D) an extracellular form. 1000× magnification. Adapted from Vannier and Krause (2012) (From The New England Journal of Medicine, Edouard Vannier, PhD., and Peter J. Krause, M. D., Human Babesiosis, 366, 2399. Copyright (2012) Massachusetts Medical Society. Reprinted with permission).

which is the earliest branching clade of the Babesia-Theileria-Cytauxzoon complex. This clade includes four distinct lineages within it: Clade Ia parasites that infect rodents, monkeys and humans (e.g., B. microti; the primary agent of human babesiosis); Clade Ib parasites that infect canids and mustelids (e.g., Babesia vulpes); Clade Ic parasites that infect rodents (e.g., Babesia rodhaini); and Clade Id parasites that infect cats (e.g., Babesia felis). Like other piroplasms, clade I Babesia show transtadiational transmission but lack transovarial transmission typical of the "classic Babesia" of clade X (Babesia species "sensu stricto"). In addition to the Clade I B. microti-like group, clades of other human-infecting piroplasms include members of Clade III (the "Western group") with representatives like B. duncani, Clade IX comprised of Theileria sensu stricto (e.g., T. annulata, T. parva, and T. orientalis), and Clade X consisting of Babesia sensu stricto (e.g., B. divergens and B. venatorum). With over 90 species infecting a variety of wild and domestic mammalian hosts (Schnittger et al., 2012), several piroplasms have a significant worldwide veterinary economic impact. These include: (1) the bovine-infecting species, e.g., B. bigemina, B. bovis, and B. divergens; (2) the equid-infecting species, e.g., Theileria equi and Babesia caballi; (3) sheep/goat-parasites, e.g., Babesia ovis and B. crassa; and (4) carnivoran parasites, e.g., B. felis and B. canis (for review see Schnittger et al., 2012).

Given the distinct features of the B. microti and B. microti-like group from the Babesia sensu stricto group, it has been argued that in a future taxonomic revision the B. microti and B. microti-like group should be elevated to a separate genus along with the other distinct clades identified in recent studies (Rudzinska, 1976; Rudzinska et al., 1976; Goethert and Telford, 2003; Cornillot et al., 2012; Lack et al., 2012; Schnittger et al., 2012; Jalovecka et al., 2019). Additional studies are needed that include the creation of a large database of whole genome sequencing of Babesia spp. This will provide a complete examination of the genetic diversity of Babesia spp. that have such a significant worldwide public health impact.

GENETIC VARIABILITY IN Babesia microti POPULATIONS

Genomic studies over the past decade have refined our understanding of the epidemiological characteristics of B. microti. In one study, genome sequence analyses of 42 B. microti samples from around the world show extensive genetic diversity (Lemieux et al., 2016). B. microti isolates from within the continental United States show a relatively stable genetic structure but these isolates possess significant genetic diversity compared with samples from geographically distant Alaska, Russia, and Japan. In the continental United States, two distinct genetic B. microti subpopulations were noted in the Northeast and Midwest regions. The authors predicted that these two parasite lineages entered the continent at different time points separated by more than...
700 years (Lemieux et al., 2016). In the same study, parasite variants containing amino acid substitutions in the rp14, a subunit of riboendonuclease, were associated with relapsing disease. Additionally, genetic mutations in the atovaquone-binding regions of cytochrome b and the azithromycin-binding region of ribosomal protein subunit L4 were also identified. Based on the available whole genome wide sequence data, a 25 single nucleotide polymorphism (SNP) barcode was subsequently developed that supported the previous findings and identified two distinct *B. microti* lineages in the northeastern and midwestern United States (Baniecki et al., 2019).

The genetic diversity and population structure of *B. microti* parasites in the endemic regions of the northeastern United States has been characterized by Carpi et al. (2016). They employed the multiplex capture platform for characterizing genome-wide diversity and genetic relatedness in 25 *B. microti* isolates obtained from tick-vectors and humans. Their results showed that in the northeastern United States, *B. microti* was strongly structured into three highly differentiated genetic clusters. Interestingly, analyses of the apicoplast genome indicated that in the Northeast, the current genetic diversity in *B. microti* dates back 46,000 years with evidence of population expansion in the past 1,000 years (Carpi et al., 2016). In another study, a total of 228 *B. microti* patient isolates from the New England area were genotyped by using variable number tandem repeat markers. Their results also showed the presence of three distinct *B. microti* population structures with each dominated by a single ancestral type (Goethert et al., 2018). The authors concluded that *B. microti* parasites prevalent in the northeastern United States have expanded from a common ancestral origin(s) on the mainland and not from Nantucket or other islands off the New England mainland where babesiosis was first reported to be endemic.

In summary, the genetic variability of *B. microti* in the United States is limited and different from *B. microti* in other parts of the world. *B. microti* can be divided into northeastern and midwestern groups with further division of three genetic clusters in the Northeast. It remains to be determined whether these closely related but different genetic groups are associated with different clinical severity.

### Babesia microti Antigenic Polymorphism and Immunodominant Antigens

The publicly available whole *B. microti* genome sequence database is still limited and the majority of information
comes from parasite isolates collected in endemic areas in United States. In one study, genomics and gene expression profiling experiments were performed to identify polymorphic genes involved in host–parasite interactions. Analyses based on seven B. microti isolates from the northeastern United States revealed that antigenic polymorphism is generally restricted to a small number of highly expressed genes which belonged to the parasite surface proteome and secretome (Silva et al., 2016). Among the 3568 protein coding genes, 205 genes carried a total of 257 amino acid altering mutations, 27 of which contained nearly all mutations (Silva et al., 2016). It is possible that these surface expressed antigens are major immune targets and subjected to antigen variation that allows the parasite to escape host immunological surveillance and establish long term chronic infection.

In the past two decades, several groups have made efforts to identify and characterize immunodominant B. microti antigens to study their potential role as mediators of immunity and pathogenesis and for diagnostic and vaccine use. The majority of currently available antigens have been identified by screening B. microti genomic expression libraries against sera from infected mice or humans (Lodes et al., 2000; Homer et al., 2003; Xu et al., 2018; Zhou et al., 2018; Verma et al., 2020). The most prominent among these proteins are the diverse polymorphic multigene antigens termed the BMN (B. microti MN1 strain seroreactive antigen) family of antigens. Sequence analyses revealed patient-to-patient variation in the number and location of the sequence repeats within the BMN1-6 homolog. Furthermore, parasite isolates from nearby geographical locations were genetically similar compared to those from geographically distant locations (Lodes et al., 2000).

In two recent reports, immuno-screening of protein arrays based on B. microti antigen expressed in Escherichia coli has led to identification of several immuno-reactive antigens, some of which were previously uncharacterized (Xu et al., 2018; Zhou et al., 2018). In another study, Elton et al. (2019) employed a mammalian expression system to identify 54 genes that are predicted to encode surface and secreted B. microti blood stage antigens. The recombinant antigens produced were conformationally dependent and were used to measure the kinetics of antibody responses during early and late phase B. microti infection in BALB/c mice. Antibody responses against several antigens were noted during the entire course of infection. While some mice were able to mount antibody responses against all immunoreactive antigens, other mice generated antibody responses against only a subset of antigens. These results are surprising because the mice used in the study were major histocompatibility (MHC) compatible. Some immunoreactive antigens continued to elicit antibody responses beyond day 125 following initial infection. Interestingly, a broadly similar profile of antibody reactivity was observed against the same antigen panel in serum samples obtained from mice that were infected with a genetically distant strain of B. microti. A heterogenic antibody response against a subset of these antigens also was observed in sera from babesiosis patients, although the sample size was too small to draw any firm conclusions.

Several studies have applied computational and bioinformatics analyses to predict B. microti proteins that could be involved in host–parasite interactions, immune evasion, and potential targets of antigenic polymorphism. Using this approach, Silva et al. predicted 420 proteins that putatively belonged to the B. microti secretome (Silva et al., 2016). Next, a protein array was constructed consisting of 174 proteins that are predicted to trigger immune responses in hosts during infection. Immuno-screening using sera from B. microti-infected mice identified 30 highly antigenic proteins. Fourteen of 30 proteins, including the two most antigenic proteins, were a part of the secretome (Silva et al., 2016). In a subsequent study using a 17-plex protein array based on glycosylphosphatidylinositol (GPI)-anchored proteins, BmGP12 was identified as a potential biomarker for detection of past or current B. microti infections in laboratory and field captured mice, as well as in babesiosis patients and healthy residents living in New England (Cornillot et al., 2016).

In a more recent study of B. microti immunodominant antigens, genome-wide immune-screening led to the discovery of 56 novel B. microti antigens, many previously uncharacterized (Verma et al., 2020). Five immunodominant B. microti proteins that were identified in the study were cell-surface proteins possessing antigenic extracellular domains characteristic of adherence proteins that interact with host proteins. For instance, one of these is a previously uncharacterized protein with four copies of the epidermal growth factor (EGF) domains BmEGF1 (BmR1_03g00690). While EGF domain repeat proteins are widely known in Apicomplexa (Anantharaman et al., 2007), this protein is not closely related to any of them and its EGF domains share specific features in the pattern of conserved cysteines with certain proteins from Giardia intestinalis and animal secreted proteins (Verma et al., 2020). Consistent with this data, confocal microscopy studies showed that two of these antigens were expressed on the surface of infected erythrocytes, raising the possibility of their role as cytoadherence antigens. A combination of these two novel antigens and one previously described antigen provided 96% sensitivity and 100% specificity in detecting B. microti specific antibodies in babesiosis patients using an enzyme-linked immunosorbent assay (ELISA) platform (Verma et al., 2020).

Two of these five immunodominant proteins that are the most reactive B. microti antigens (BmR1_03g04855 and BmR1_03g00785) belong to the BMN class of proteins (Lodes et al., 2000; Homer et al., 2003; Silva et al., 2016; Xu et al., 2018; Zhou et al., 2018; Verma et al., 2020). A comprehensive analysis of these proteins shows that BMN class proteins do not constitute a monophyletic group and should not be considered as a unified “BMN family.” Instead, the majority can be classified into multiple evolutionarily unrelated groups of BMN proteins.

The first major group of BMN proteins generally correlate with the following families: (i) BMN1–10, N1–10, BMN1–4, BMN1–3B, BMN1–8, and BMN1–11 proteins from the B. microti MN1 strain, (ii) the IRA protein from the B. microti Gray strain and, (iii) the Br-1 and Br-2 proteins from the B. rodhaini Japanese strain. These proteins correspond in large part to the antigens termed BMN1 by Silva et al. (2016). B. microti R1 was found
to possess 10 members of this group, including BmR1_03g04855 (Table 3 in Verma et al., 2020). They are characterized by one to five copies per protein of a domain with a N-terminal 8 β-strand sandwich, followed by a C-terminal disulfide bond-supported structure. Divergent versions of this domain are found outside of the B. microti-like strain, in a group of secreted proteins expanded across Theileria. Hence, this domain was named piroplasm β-strand (PiβS) domain.

The second group of BMN proteins is comprised of BMN1-2, BMN1-3, BMN1-6, BMN1-7, BMN1-9, BMN1-13, BMN1-4, MN-10, N1-21, all from the B. microti MN1 strain; BmSA1 from the B. microti Gray strain; BmP32 from the B. microti Munich strain; MSA1 and MSA2 from B. rodhaini Australia strain; and Br-1, p25, and p26 from the B. rodhaini Japanese strain. The Br-1, p25, and p26 proteins correspond in large part to the antigens termed BMN2 by Silva et al., 2016. Nine proteins in the second group of BMN proteins are present in the B. microti R1 strain (Table 3 in Verma et al., 2020). These are distinguished by a novel B. microti-like group-specific extracellular domain with 9 α-helices and a C-terminal hydrophobic GPI-anchor. Accordingly, it was named the Babesia α-helical cell surface (BAHCS) domain. In contrast to the PiβS domain, the BAHCS domain is always found in a single copy in a protein; however, on occasions both these domains might occur in the same protein (e.g., Br-1 from B. rodhaini and its cognate BMN1-4 from the B. microti MN1 strain). Both the PiβS and BAHCS domains shows a similar evolutionary tendency for independent lineage-specific expansions in B. rodhaini and B. microti along with notable inter-strain radiations in the later species (Verma et al., 2020). Beyond these, smaller BMN groups are formed by the paralogous BMN1-17 and BMN1-20 proteins and the Maltese cross form-related antigen (BMN1-15/N1-15) and BmR1_02g04285 (BmMCFRP1) that are unrelated to these groups (Verma et al., 2020).

The biological relevance of the antigenically polymorphic BMN family antigens and other immunodominant family antigens, as well as other adherence antigens in B. microti parasites, remains to be determined. Their rapid evolution in phylogenetically close lineages and independent lineage-specific expansions between them are the hallmark of proteins in an arms race with the host. This is reminiscent of other apicomplexan surface proteins such as the rifin-like and the var/DBL1 superfamilies in P. falciparum, and the vir/yir superfamilies in Plasmodium vivax/P. yoelii (Anantharaman et al., 2007). Future studies are needed to determine whether any of these antigens expressed on the surface of B. microti-infected red blood cells contribute to an immune escape mechanism that leads to persistent infections in animals and humans.

While data on B. microti proteins that are derived from genomic studies are now expanding, our knowledge of the parasite proteome based on direct protein profiling is very limited. By applying a combination of nanotechnology and mass spectroscopy (MS), Magni et al. (2019) have generated a proteome profile of intraerythrocytic B. microti parasites during acute phase infection in hamsters. They have identified ~500 proteins with assigned functions, such as transport, carbohydrate and energy metabolism, signaling transport, mobility and invasion, and immune response. This proteome database could be exploited for novel diagnostic and vaccine targets and better understanding of parasite biology, host immunity, and pathogenesis. In a subsequent study, the nanotechnology-MS methods were applied to identify B. microti proteins in blood, serum and urine during infection in hamsters (Magni et al., 2020). A distinct but less abundant protein profile was observed in urine compared to blood and plasma. These studies highlight the potential value of the nanoparticle-MS methods to detect B. microti proteins in complex analytes such as blood and plasma.

Overall, data from whole genome, parasite genotyping, and expression profiling studies are helping to develop genetic tools for surveillance of acute and asymptomatic B. microti infections and for monitoring transmission in new endemic areas. Such studies are also expanding our knowledge of B. microti antigens that perform important functions, such as inducing protective immune responses and mediating host pathogenesis.

**Babesia microti PATHOGENESIS GENOMICS**

The pathogenesis of Babesia spp. infections in humans is multifactorial, complex, and incompletely understood. In particular, molecular processes that underlie pathogenic mechanisms in human babesiosis have not been well researched. Pathogenesis studies are complicated by variation in pathogenic mechanisms for different Babesia spp. and variation in the immunologic status and pathophysiologic response of hosts. Three clinical patterns of human babesiosis have been described: acute symptomatic disease which may be mild, moderate or severe, acute asymptomatic infection, and persistent infection (Vannier et al., 2008; Vannier and Krause, 2012). Acute asymptomatic infection is the most common clinical presentation. Asymptomatic infection occurs in about 20% of adults and is characterized by low parasitemia. Persistent infection follows acute symptomatic or asymptomatic infection and may last as long as 2 years (Krause et al., 1998, 2007; Raffalli and Wormser, 2016).

**Acute Disease**

Several mechanisms may account for the severity of acute B. microti infection: an aberrant immune response that include excessive pro-inflammatory cytokine release, erythrocyte cytoadherence, persistent infection, and hemolytic anemia.

**Aberrant Immune Response, Cytokine Storm**

It is well recognized that immune responses that help protect the host against invading pathogens can also contribute to severe disease (Yokota, 2003; Huang et al., 2005). Over production of several pro-inflammatory cytokines during an array of infections is often associated with acute inflammation and tissue damage in the microenvironement of the lungs and other organs (Rubinfield et al., 2005). The phenomenon of hyperimmune immune responsiveness leading to excessive cytokine production has been termed “cytokine storm” and is attributed to the most severe pathogenic consequences of infections such as SARS-CoV-2 infection (Fajgenbaum and June, 2020). Key cytokines
involved in cytokine storm are TNF-α, IFN-γ, IL-1, IL-6, and IL-18. The major immune cell types involved are neutrophils, macrophages and NK cells.

Cytokine storm has been implicated in severe disease complications in babesiosis (Clark and Jacobson, 1998; Hemmer et al., 2000; Krause et al., 2007). Excessive TNF-α and IL-1 production by macrophages, Th1 lymphocytes, and other cells in response to high parasitemia, decreases capillary integrity and can cause multi-organ dysfunction, including ARDS (Hemmer et al., 2000). When the effect is more widespread with loss of intravascular fluid, hypotension and shock may result. Increased nitric oxide production following TNF-α and IL-1 release can help eradicate microbial pathogens but also cause tissue damage (Aguilar-Delfin et al., 2001; Vannier et al., 2015; Djokic et al., 2018). Elevated blood concentrations of TNF-α have been associated with the expression of adherence molecules ICAM-1 and VCAM-1 in vascular epithelium and with cerebral malaria in children (World Health Organization (WHO), 2000; Krause et al., 2007).

The genomic underpinnings of cytokine storm have just begun to be elucidated. The dynamic of cytokine production leading to cytokine storm is complex and balanced by a number of factors, including proinflammatory cytokines and their cognate soluble receptor or inhibitors and the production of anti-inflammatory cytokines such as IL-10 (Tisoncik et al., 2012). Previous genomic studies have demonstrated the upregulation of proinflammatory cytokines in animal models during influenza infection (Kash et al., 2006; Kobasa et al., 2007; Cilloniz et al., 2009). The signature cytokine genes showing strong upregulation include IL-6, IL-8, CCL2, CCL-5, CXCL10, and CXCL9 (Baskin et al., 2009; Zhou et al., 2020). More recently, genomic databases generated from transcriptome analyses of cytokines, chemokines and immune cells during acute infections, such as those caused by influenza virus, dengue viruses, SARS-CoV-2, and other pathogens have begun to provide new insights regarding events leading to cytokine storm (Afroz et al., 2016; Hancock et al., 2018; Zhou et al., 2020).

Other mechanisms that influence cytokine-mediated regulation of severe disease include the association of TNF-α promoter polymorphisms (G-238A and G-308A) with susceptibility to diseases as diverse as systemic lupus erythematosus and P. falciparum malaria (Mahto et al., 2019), as well as epigenetic regulation of cytokine storm in COVID-19 patients (Sawalha et al., 2020). Carefully designed transcriptome and cytokine profiling studies in severe babesiosis patients and in chronic asymptomatic Babesia infections would help to identify the molecular factors that lead to severe disease with fatal consequences in susceptible individuals. Such studies may help to develop immunotherapies that could ameliorate the most severe B. microti complications, such as hemolytic anemia, ARDS and kidney damage in babesiosis patients.

Erythrocyte Cytoadherence

Residence within red blood cells offers some protection for Babesia against host immune factors but Babesia infected erythrocytes are recognized and removed in the spleen. Cytoadherence of Babesia-infected erythrocytes to vascular endothelium is thought to allow the pathogen to complete its life cycle, leave the erythrocyte briefly, and infect another red blood cell without ever traversing the spleen. Excessive Babesia-induced erythrocyte adherence may contribute to babesiosis complications. Babesia-induced red cell cytoadherence has been associated with B. bovis and B. duncani induced pathology (Clark et al., 2006a; Usmani-Brown et al., 2013; Allred, 2019). B. bovis strains with increased cytoadherence activity in vitro have increased virulence in cattle (O’Connor et al., 1999). When parasitemia is high in B. bovis-infected cattle, a large number of infected red blood cells may adhere to small capillaries in the brain, causing vascular obstruction, anoxia and death of neurons. This is associated with the same stroke syndrome that is seen with cerebral malaria. Cytoadherence also has been associated with lung injury in B. duncani infected hamsters and mice (Dao and Eberhard, 1996; Hemmer et al., 1999, 2000; Krause et al., 2007), as well as renal injury in B. bovis-infected cattle (Patarroyo et al., 1982; Everitt et al., 1986). It remains unclear whether B. microti induces red blood cell cytoadherence. Vascular stasis and blockage has been demonstrated in the retina of a human patient infected with B. microti but another single case study failed to demonstrate evidence of B. microti-infected red blood cell cytoadherence to vascular endothelium in the brain of a comatose patient (Ortiz and Eagle, 1982; Clark et al., 2006b; Ortiz et al., 2020).

The genomic etiology of Babesia infected red blood cell cytoadherence has been described for B. bovis. A multigene family, ves1a, in B. bovis is responsible for the production of adherence variant erythrocyte surface antigen 1 or VESA1 (Allred et al., 2000). This family of variant proteins are found on the surface of B. bovis-infected red blood cells. A similar multigene family (var genes) is found in P. falciparum that encodes for the production of P. falciparum erythrocyte membrane protein 1 or PfEMP1 (Jensen et al., 2020). These surface proteins mediate infected erythrocyte adherence to vascular endothelium, which make Babesia and Plasmodia less accessible to attack by host immune cells (Allred and Al-Khedery, 2006; Krause et al., 2007). In a recent study, several adherence proteins have been found on the surface of B. microti-infected red blood cells in laboratory mice (Verma et al., 2020). These findings support the possibility that B. microti-induced cytoadherence may contribute to disease complications.

Persistent Infection

Persistence of infection is critical for the survival of Babesia as they rely on transfer between rodent host and tick vector. Once infected, both the primary host (Peromyscus leucopus) and tick vector (I. scapularis) remain infected for life, increasing the chance of transfer of infection from one to the other. The same mechanism(s) that ensure persistence of infection in wildlife are likely to be operative in humans as they too experience persistent infection for months, even though they are dead end hosts (Spielman et al., 1981; Telford and Spielman, 1993; Krause et al., 1998; Moritz et al., 2016). At least three mechanisms are thought to contribute to persistence: intraerythrocytic location, cytoadherence, and regulation of parasite release from the erythrocyte.
The intraerythrocytic location of *Babesia* protect them against host immune factors. Cytoadherence of *Babesia*-infected erythrocytes to vascular endothelium avoids splenic destruction of *Babesia*. Variable parasite release from the erythrocyte also contributes to persistent *Babesia* infection. The work of Lobo and colleagues has shown that the intraerythrocytic life cycle of *B. divergens* is flexible and that egress from the erythrocyte can occur rather quickly after red blood cell invasion or later in infection. Once established within the red blood cell, early egress from erythrocytes would be favored when there is a strong need to expand the population, as occurs early in infection. Later egress following several cell divisions is more likely when infection is well established and the intravascular environment becomes hostile due to host immune activation and antimicrobial therapy (Lobo et al., 2019). It only takes a few infected erythrocytes to support persistence of infection in a host, which helps explain the recrudescence of infection that can occur in immunocompromised hosts despite low level parasitemia after prolonged (6 weeks or longer) antimicrobial therapy (Krause et al., 2008).

The clinical consequences of persistent infection include relapsing disease in immunocompromised individuals and transfer of *Babesia* to blood transfusion recipients following donation from an asymptomatic infected blood donor. A prospective follow-up study of 46 babesiosis patients demonstrated that *B. microti* parasitemia can persist for months with or without anti-*B. microti* therapy (Krause et al., 1998). Blood samples were obtained from patients during acute infection and every three to 6 months thereafter for amplification of *B. microti* DNA using PCR. About half (*n* = 22) of the patients were treated with clindamycin and quinine. *Babesia* DNA persisted asymptomatically in these patients for 2–13 months, depending in part on whether parasitemia duration was measured by the last recorded PCR positive sample or the first PCR negative sample. Asymptomatic infection persisted even longer in a group of patients who had mild *B. microti* infection and were not treated because of concern about side effects of clindamycin and quinine, the only effective therapy available at the time of the study. In these cases, parasitemia duration was 7–27 months. Only one of the 46 previously healthy patients had recrudescence of infection and that occurred 27 months after initial diagnosis (Krause et al., 1998). In contrast, recrudescence is more common in highly immunocompromised patients, especially those with defective antibody production (Krause et al., 2008). Prolonged *Babesia* disease has been described in immunocompromised hosts, with relapsing symptoms lasting up to 9 months and parasitemia continuing for more than 2 years (Krause et al., 2008; Raffalli and Wormser, 2016; Allred, 2019; Bloch et al., 2019). These patients are markedly immunocompromised with underlying diagnoses that include HIV/AIDS, malignancy, and asplenia. A retrospective case series of consecutively enrolled babesiosis patients who failed to respond to standard anti-*Babesia* antibiotic therapy also demonstrated that patients with these immunosuppressive conditions experienced persistent and relapsing babesiosis (Krause et al., 2008). Interestingly, 10 of the 14 patients in this series suffered from B cell lymphoma and had been treated with Rituximab, an anti-B cell monoclonal antibody. These data suggest that an impaired anti-*Babesia* antibody response, along with generalized immunosuppression, prevents clearance of *B. microti* infection. Long term antibiotic therapy of at least 6 weeks with at least 2 weeks of negative blood smears, rather than the standard 7–10 days, was required to resolve infection in these severely immunocompromised patients. Severe and persistent *B. microti* infection has been associated with advanced age in a mouse model and in humans (Vannier et al., 2004; Vannier and Krause, 2012).

Asymptomatic persistence of *Babesia* infection accounts for transmission of *Babesia* through blood donation. In the United States, *B. microti* is one of the most common pathogens transmitted by blood transfusion. Since 1979, there have been more than 250 cases of transfusion-transfusion transmitted babesiosis (Herwaldt et al., 2011; Moritz et al., 2016; Linden et al., 2018; Gray and Herwaldt, 2019). Furthermore, data from several studies, including the national babesiosis surveillance program that tracks clinical cases, indicate that both the clinical burden and foci of transmission of *Babesia* are expanding, which also means increased transfusion transmitted babesiosis risk to the U.S. blood supply (Menis et al., 2015; Linden et al., 2018; Gray and Herwaldt, 2019). Lack of knowledge of the mechanisms of persistence of parasitemia in asymptomatic carriers, and the intraerythrocytic characteristics of the parasite, present unique challenges in identifying *Babesia* infection in blood donors. While the minimum infectious dose to transmit *Babesia* in humans is not known, results from a mouse model suggest that as few as 10–100 infected RBC are sufficient to establish fulminant blood stage infection (Bakkour et al., 2018).

Limited epidemiological surveys in *Babesia*-endemic states using laboratory-based nucleic-acid-based tests (NAT) and antibody testing have provided important information about the percentage of asymptomatic infected donors, the relationship between seropositivity and parasitemia, and the seasonality of transmission in endemic areas (Leiby et al., 2005, 2014; Johnson et al., 2009). In more recent years, results from prospective studies in large cohorts of blood donors conducted under the Investigational New Drug protocols have shed light on the prevalence of *B. microti* infections in asymptomatic healthy adults in endemic areas and non-endemic states (Levin et al., 2016; Moritz et al., 2016; Tonnetti et al., 2020). Results showed one confirmed infected sample per 1331 donations in endemic states (67 positives/89,153 donations) (Moritz et al., 2014) and one confirmed positive per 2351 donations (211 positives/496,270 donations) (Tonnetti et al., 2020) in endemic states plus Florida using investigational NAT assays. Cumulative results from the surveillance programs (Herwaldt et al., 2011; Linden et al., 2018; Gray and Herwaldt, 2019) and donor testing studies (Johnson et al., 2009; Moritz et al., 2016) have revealed that while tick-borne infections are seasonal, transfusion transmitted cases occur year-round, although they too peak during the tick-transmission season. Transfusion transmitted babesiosis cases are also reported outside the bounds of recognized endemic states due to travel to endemic areas from non-endemic areas and import of blood products from endemic to non-endemic states (Cangelosi et al., 2008; Ngo and Civen, 2009).
Babesia Genomic sequencing of hypercoagulability have not been investigated. of the severity of babesiosis-induced hemolytic anemia and of autoimmunity (Woolley et al., 2017). The genetic aspects in a subset of asplenic patients who had no previous history 4 weeks after the diagnosis of babesiosis has been described Hemolytic anemia due to production of autoantibodies 2–babesiosis patients (Persing et al., 1995; Hatcher et al., 2001). Hemolytic anemia due to production of autoantibodies 2–4 weeks after the diagnosis of babesiosis has been described in a subset of asplenic patients who had no previous history of autoimmunity (Woolley et al., 2017). The genetic aspects of the severity of babesiosis-induced hemolytic anemia and hypercoagulability have not been investigated.

CONCLUSION

Genome sequencing of Babesia parasite isolates from diverse geographic locations has improved our understanding of genetic diversity of Babesia and provided genetic tools to monitor the areas of transmission and expansion where the disease had not previously existed. Genomic studies also have helped elucidate the pathogenesis of B. bovis and B. divergens infections that may have relevance for all pathogenic Babesia species. Such studies also have provided potential therapeutic and vaccine targets. Computational analyses and biological characterization of novel B. microti antigens has made possible the assignment of functions and elucidation of biological pathways that could provide new diagnostic tools and novel drug and vaccine targets. Availability of superior detection assays will allow improved diagnosis for acute babesiosis and help protect the blood supply against transfusion-transmitted babesiosis. Additional research is needed to improve our knowledge of parasite invasion, cell cycle and proliferation, and factors that mediate host immunity and pathogenesis. Finally, genomic studies should help in the development of novel treatment options. These include new drugs and/or biologics such as monoclonal antibodies that are urgently needed for treatment of those patients experiencing severe babesiosis in whom standard anti-Babesia antibiotics are not effective.

AUTHORS CONTRIBUTIONS

SK and PK conceptualized the review, analyzed the data, and helped to write the manuscript. AP, SB, LA, and SM helped to write the manuscript and prepared the figures. All authors read and approved the final manuscript.

ACKNOWLEDGMENTS

The authors thank the FDA Intramural Research Program and the Gordon and Luhr Gad Foundation for providing financial support. The views and opinions expressed here are those of authors and do not represent the official position of the FDA.

REFERENCES

Adl, S. M., Bass, D., Lane, C. E., Lukes, J., Schoch, C. L., Smirnov, A., et al. (2019). Revisions to the Classification, Nomenclature, and Diversity of Eukaryotes. J. Eukaryot. Microbiol. 66, 4–119.

Afroz, S., Giddaluru, J., Abbas, M. M., and Khan, N. (2016). Transcriptome meta-analysis reveals a dysregulation in extra cellular matrix and cell junction associated gene signatures during Dengue virus infection. Sci. Rep. 6:33752.

AgUILAR-Delfin, I., Homer, M. J., Wettstein, P. J., and Persing, D. H. (2001). Innate resistance to Babesia infection is influenced by genetic background and gender. Infect. Immun. 69, 7955–7958. doi: 10.1128/iai.69.12.7955-7958.2001

Allred, D. R. (2019). Variable and Variant Protein Multigene Families in Babesia bovis Persistence. Pathogens 8:76. doi: 10.3390/pathogens8020076

Allred, D. R., and Al-Khedery, B. (2004). Antigenic variation and cytoadhesion in Babesia bovis and Plasmodium falciparum: different logics achieve the same goal. Mol. Biochem. Parasitol. 134, 27–35. doi: 10.1016/j.molbiopara.2003.09.012

Allred, D. R., and Al-Khedery, B. (2006). Antigenic variation as an exploitable weakness of babesial parasites. Vet. Parasitol. 138, 50–60. doi: 10.1016/j.vetpar.2006.01.039

Allred, D. R., Carlton, J. M., Satcher, R. L., Long, J. A., Brown, W. C., Patterson, P. E., et al. (2000). The ves multigene family of B. bovis encodes components of rapid antigenic variation at the infected erythrocyte surface. Mol. Cell 5, 153–162. doi: 10.1016/s1097-2765(00)80411-6

Anantaraman, V., Iyer, L. M., Balaji, S., and Aravind, L. (2007). Adhesion molecules and other secreted host-interaction determinants in Apicomplexa: insights from comparative genomics. Int. Rev. Cytol. 262, 1–74. doi: 10.1016/s0074-7696(07)62001-4

Bakkour, S., Chafets, D. M., Wen, L., Muench, M. O., Telford, S. R. III., Erwin, J. L., et al. (2018). Minimal infectious dose and dynamics of Babesia microti parasiDine in a murine model. Transfus 58, 2903–2910. doi: 10.1111/trf.14889

Banicek, M. L., Moon, J., Sani, K., Lemieux, J. E., Schaffner, S. F., and Sabeti, P. C. (2019). Development of a SNP barcode to genotype Babesia microti infections. PLoS Negl. Trop. Dis. 13:e0007194. doi: 10.1371/journal.pntd.0007194

Baskin, C. R., Bielefeldt-Ohmann, H., Tumpey, T. M., Sabourin, P. J., Long, J. P., Garcia-Sastre, A., et al. (2009). Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc. Natl. Acad. Sci. U. S. A. 106, 3455–3460. doi: 10.1073/pnas.0813234106

Bloch, E. M., Kumar, S., and Krause, P. J. (2019). Persistence of Babesia microti Infection in Humans. Pathogens 8:102. doi: 10.3390/pathogens8030102

Brennan, M. B., Herwaldt, B. L., Kazmierczak, J. J., Weiss, J. W., Klein, C. L., Leith, C. P., et al. (2016). Transmission of Babesia microti Parasites by Solid Organ Transplantation. Emerg. Infect. Dis. 22, 1869–1876.

Bunnik, E. M., Cook, K. B., Varoquaux, N., Batugedara, G., Prudhomme, J., Cort, A., et al. (2018). Changes in genome organization of parasite-specific gene bands of the Plasmodium transmission stages. Nat. Commun. 9:1910.
Magni, R., Luchini, A., Liotta, L., and Molestina, R. E. (2019). Analysis of the
Lemieux, J. E., Tran, A. D., Freimark, L., Schaffner, S. F., Goethert, H., Andersen,
Leiby, D. A., Chung, A. P., Gill, J. E., Houghton, R. L., Persing, D. H., Badon, S.,
Mahto, H., Tripathy, R., Meher, B. R., Prusty, B. K., Sharma, M., Deogharia, D.,
et al. (2019). Proteomic analysis
Linden, J. V., Prusinski, M. A., Crowder, L. A., Tonnetti, L., Stramer, S. L.,
Krause, P. J., Gewurz, B. E., Hill, D., Marty, F. M., Vannier, E., Foppa, I. M., et al.
Krause, P. J., Lepore, T., Sikand, V. K., Gadbaw, J. Jr., Burke, G., Telford, S. R., III,
et al. (2000). Atovaquone and azithromycin for the treatment of babesiosis.
N. Engl. J. Med. 343, 1454–1458. doi: 10.1056/nejme200011163432004
Krause, P. J., Spielman, A., Telford, S. R. III, Sikand, V. K., Mckay, K., Christianion,
et al. (1998). Persistent parasitemia after acute babesiosis. N. Engl. J. Med.
339, 160–165. doi: 10.1056/nejm199806013390030
Lack, J. B., Reichard, M. V., and Van Den Bussche, R. A. (2012). Phylogeny and
evolution of the Plasmodiida as inferred from 18S rRNA sequences. Int. J.
Parasitol. 42, 353–363. doi: 10.1016/j.ijpara.2012.02.005
Leiby, D. A., Chung, A. P., Gill, J. E., Houghton, R. L., Persing, D. H., Badon, S.,
et al. (2005). Demonstrable parasitemia among Connecticut blood donors with
antibodies to Babesia microti. Transfusion 45, 1804–1810. doi: 10.1111/j.1537–
2995.2005.00609.x
Leiby, D. A., Johnson, S. T., Won, K. Y., Nace, E. K., Smelenda, S. B., Piencejak,
et al. (2014). A longitudinal study of Babesia microti infection in seropositive blood donors. Transfusion 54, 2217–2225. doi: 10.1111/trf.12622
Lemieux, J. E., Tran, A. D., Freimark, L., Schaffner, S. F., Goethert, H., Andersen,
K. G., et al. (2016). A global map of genetic diversity in Babesia microti reveals
strong population structure and identifies variants associated with clinical
relapse. Nat. Microbiol. 1:16079.
Lena, T., and Le Roch, K. G. (2019). Three-Dimensional Genome Organization and
Virulence in Apicomplexa Parasites. Epigenet. Insights 12:2516685719879436.
Levin, A. E., Williamson, P. C., Bloch, E. M., Clifford, J., Cyrus, S., Shar, B. H.,
et al. (2016). Serologic screening of United States blood donors for Babesia microti
using an investigational enzyme immunoassay. Transfusion 56, 1866–1874.
doi: 10.1111/trf.13618
Linden, J. V., Prusinski, M. A., Crowder, L. A., Tonnelli, L., Stramer, S. L.,
Kessler, D. A., et al. (2018). Transfusion-transmitted and community-acquired
babesiosis in New York, 2004 to 2015. Transfusion 58, 660–668. doi: 10.1111/trf.14476
Liu, J., Guan, G., Li, Y., Liu, A., Luo, J., and Yin, H. (2017). A Molecular Survey of
Babesia Species and Detection of a New Babesia Species by DNA Related to
B. venatorum from White Yaks in Tianzhu, China. Front. Microbiol. 8:419. doi:
10.3389/fmicb.2017.00419
Lobo, C. A., Cursino-Santos, J. R., Singh, M., and Rodriguez, M. (2019). Babesia
divergens: a Drive to Survive. Pathogens 8:95. doi: 10.3390/pathogens8030095
Lodes, M. J., Houghton, R. L., Brunsma, E. S., Mohamath, R., Reynolds,
L. D., Benson, D. R., et al. (2000). Serological expression cloning of novel
immunoreactive antigens of Babesia microti. Infect. Immun. 68, 2793–2790.
doi: 10.1128/iai.68.5.2783-2790.2000
Magni, R., Luchini, A., Liotta, L., and Molesteina, R. E. (2019). Analysis of the
Babesia microti proteome in infected red blood cells by a combination of
naotechnology and mass spectrometry. Int. J. Parasitol. 49, 139–144. doi: 10.1016/j.ijpara.2018.08.004
Magni, R., Luchini, A., Liotta, L., and Molesteina, R. E. (2020). Proteomic analysis
reveals pathogen-derived biomarkers of acute babesiosis in erythrocytes,
plasma, and urine of infected hamsters. Parasitol. Res. 119, 2227–2235. doi:
10.1007/s00436-020-06712-5
Mahto, H., Tripathy, R., Meher, B. R., Prusty, B. K., Sharma, M., Deogharia, D.,
et al. (2019). TNF-alpha promoter polymorphisms (G-238A and G-308A) are
associated with susceptibility to Systemic Lypus Erythematosus (SLE) and P.
falciparum malaria: a study in malaria endemic area. Sci. Rep. 9:11752.
Shih, C. M., Liu, L. P., Chung, W. C., Ong, S. J., and Wang, C. C. (1997). Human babesiosis in Taiwan: asymptomatic infection with a Babesia microti-like organism in a Taiwanese woman. J. Clin. Microbiol. 35, 450–454. doi: 10.1128/jcm.35.2.450-454.1997

Silva, J. C., Cornillot, E., McCracken, C., Usmani-Brown, S., Dwivedi, A., Ifeoun, O. O., et al. (2016). Genome-wide diversity and gene expression profiling of Babesia microti isolates identify polymorphic genes that mediate host-pathogen interactions. Sci. Rep. 6, 35284.

Simon, M. S., Westblad, L. F., Dziedzicze, A., Visone, J. E., Furman, R. R., Jenkins, S. G., et al. (2017). Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia. Clin. Infect. Dis. 65, 1222–1225. doi: 10.1093/cid/cix477

Skrabalo, Z., and Deamovic, V. (1957). Piroplasmosis in man; report of a case. Doc. Med. Geogr. Trop. 9, 11–16.

Spielman, A., Etkind, P., Piesman, J., Rubeush, T. K. II., Juraneck, D. D., and Jacobs, M. S. (1981). Reservoir hosts of human babesiosis on Nantucket Island. Am. J. Trop. Med. Hyg. 30, 560–565. doi: 10.4269/ajtmh.1981.30.560

Telford, S. R. III., and Spielman, A. (1993). Reservoir competence of white-footed mice for Babesia microti. J. Med. Entomol. 30, 223–227. doi: 10.1093/jmedent/30.1.223

Tisoncik, J. R., Korth, M. J., Simmons, C. P., Farrar, J., Martin, T. R., and Katze, M. G. (2012). Into the eye of the cytokine storm. Microbiol. Mol. Biol. Rev. 76, 16–32.

Tonnetti, L., Young, C., Kessler, D. A., Proctor, M. C., et al. (2020). Transcription-mediated amplification blood donation screening for Babesia. Transfusion 60, 317–325. doi: 10.1111/trf.15630

Usmani-Brown, S., Halperin, J. J., and Krause, P. J. (2013). Neurological manifestations of human babesiosis. Handb. Clin. Neurol. 114, 199–203. doi: 10.1016/b978-0-444-53490-3.00014-5

Vannier, E., Diuk-Wasser, M. A., Ben Mamoun, C., and Krause, P. J. (2015). Babesiosis. Infect. Dis. Clin. North Am. 29, 357–370.

Vannier, E., and Krause, P. J. (2012). Human babesiosis. N. Engl. J. Med. 366, 2397–2407.

Vannier, E., Borggraefe, I., Telford, S. R. III., Menon, S., Brauns, T., Spielman, A., et al. (2004). Age-associated decline in resistance to Babesia microti is genetically determined. J. Infect. Dis. 189, 1721–1728. doi: 10.1086/382965

Vannier, E., Gewurz, B. E., and Krause, P. J. (2008). Human babesiosis. Infect. Dis. Clin. North Am. 22, 469–488.

Verma, N., Puri, A., Essuman, E., Skelton, R., Anantharaman, V., Zheng, H., et al. (2020). Antigen Discovery, Bioinformatics and Biological Characterization of Novel Immunodominant Babesia microti Antigens. Sci. Rep. 10:9598.

Woolley, A. E., Montgomery, M. W., Savage, W. J., Achebe, M. O., Dunford, K., Villeda, S., et al. (2017). Post-Babesiosis Warm Autoimmune Hemolytic Anemia. N. Engl. J. Med. 376, 939–946.

World Health Organization (WHO). (2000). Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans. R. Soc. Trop. Med. Hyg. 94, S1–S90.

Wormser, G. P., Prasad, A., Neuhaus, E., Joshi, S., Nowakowski, J., Nelson, J., et al. (2010). Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection. Clin. Infect. Dis. 50, 381–386. doi: 10.1086/649859

Xu, B., Liu, X. F., Cai, Y. C., Huang, J. L., Zhang, R. X., Chen, J. H., et al. (2018). Screening for biomarkers reflecting the progression of Babesia microti infection. Parasit. Vectors 11:379.

Yokota, S. (2003). [Influenza-associated encephalopathy–pathophysiology and disease mechanisms]. Nihon Rinsho 61, 1953–1958.

Zhou, X., Huang, J. L., Shen, H. M., Xu, B., Chen, J. H., and Zhou, X. N. (2018). Immunomics analysis of Babesia microti protein markers by high-throughput screening assay. Ticks Tick Borne Dis. 9, 1468–1474. doi: 10.1016/j.ttbdis.2018.07.004

Zhou, X., Xia, S., Huang, J. L., Tambo, E., Zhuge, H. X., and Zhou, X. N. (2014). Human babesiosis, an emerging tick-borne disease in the People’s Republic of China. Parasit. Vectors 7:509. doi: 10.1186/preject-1503099832120211

Zhou, Z., Ren, L., Zhang, L., Zhong, J., Xiao, Y., Jia, Z., et al. (2020). Heightened In innate Immune Responses in the Respiratory Tract of COVID-19 Patients. Cell Host Microbe 27, 883–890.e2.